A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections

StatusNot Yet Recruiting
PhaseNot specified
SponsorAbbVie
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
AbbVie
349 trials monitored
See 27 trials at risk
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
DLBCL
706 trials monitored
See 46 trials at risk
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma. This study will assess adverse events and change in disease activity in adult Korean participants with DLBCL under routine clinical practice. Epcoritamab is an approved drug for the treatment of DLBCL and FL. Approximately 175 adult participants who are prescribed epcoritamab by their doctors will be enrolled sites in Korea. Participants will receive epcoritamab as prescribed by their physician. Participants will be followed for up to 24 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Trial Details
NCT Number NCT07862764
Lead Sponsor AbbVie
Conditions
(from sponsor)		 Diffuse Large B-Cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse, Neoplasms
Enrollment 175 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov